|
|
 |
|
Viewing report
|
|
|
|
The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
Bioseeker, Nov 2005
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics.
Scope of this report
Thorough examination of the top eight cancer therapeutic antibodies on the market.
The race towards the next generation of therapeutic antibodies and improved drug delivery methods there of.
Antibody deals are on the rise, where of those targeting oncology is the single most active area.
Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Research and analysis highlights
The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.
Key reasons to read this report
One source to the top cancer therapeutic antibodies on the market.
Key insights into the second wave in the lucrative field of therapeutic antibodies.
Competitive landscape assessment, including deals, technologies and more than 100 companies in the field and close to 100 cancer therapeutic antibodies.
|
|
|
|
